

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Non-neutralizing secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon BNT162b2 vaccination

Juliana Gonçalves¹, A. Margarida Juliano^{1,*}, Nádía Charepe^{2,*}, Marta Alenquer³,
Diogo Athayde⁴, Filipe Ferreira³, Margarida Archer⁴, Maria João Amorim³, Fátima
Serrano², Helena Soares^{1,#}

¹Human Immunobiology and Pathogenesis Group CEDOC, NOVA
Medical School | Faculdade de Ciências Médicas, NOVA University of Lisbon,
Portugal

²Centro Hospitalar Universitário Lisboa Central

³Cell Biology of Viral Infection Lab, Instituto Gulbenkian de Ciência, Oeiras,
Portugal

⁴Membrane Protein Crystallography Laboratory, Instituto de Tecnologia Química
e Biológica, ITQB-NOVA. Oeiras, Portugal

*Equal contribution

#Corresponding Author: Helena Soares, Laboratory of Human Immunobiology
and Pathogenesis, CEDOC-Chronic Diseases Research
Center, Rua Câmara Pestana, 6 1150-082 Lisbon,
Portugal. helena.soares@nms.unl.pt

Highlights

- Milk and blood responses to BNT162b2 vaccine are initially isotype discordant
- Immune transfer via milk to suckling infants occurs by spike-reactive SIgA and T cells
- Spike-reactive SIgA in the breastmilk is non-neutralizing and T-cell independent
- Lactating vs non-lactating HCW had distinct cellular responses, despite similar NT50

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 **Abstract**

35

36 In view of data scarcity to guide decision-making in breastfeeding women, we
37 evaluated how mRNA vaccines impact immune response of lactating health care
38 workers (HCW) and the effector profile of breast milk transferred immune
39 protection. We show that upon BNT162b2 vaccination, immune transfer via milk
40 to suckling infants occurs through secretory IgA (SIgA) and T cells. Functionally,
41 spike-SIgA was non-neutralizing and its titers were unaffected by vaccine
42 boosting, indicating that spike-SIgA is produced in a T-cell independent manner
43 by mammary gland. Even though their milk was devoid of neutralizing antibodies,
44 we found that lactating women had higher frequencies of RBD-reactive circulating
45 memory B cells and more RBD-IgG antibodies, when compared to controls.
46 Nonetheless, blood neutralization titers in lactating and non-lactating HCW were
47 similar. Further studies are required to determine transferred antibodies and
48 spike-T cells complete functional profile and whether they can mediate protection
49 in the suckling infant.

50

51 **Keywords:**

52 BNT162b2 vaccine; lactating HCW; breastmilk; blood; milk transferred SARS-
53 CoV-2 protection; spike-reactive non-neutralizing SIgA; milk transferred spike
54 reactive T cells; memory B cells; plasmablasts

55

56

57 **Introduction**

58

59 Initial COVID-19 clinical trials of mRNA vaccines excluded lactating women,
60 causing a dearth of data to guide vaccine decision-making by health authorities

61 ¹. Even after vaccine emergency authorization, breastfeeding HCW have been
62 advised to discontinue breastfeeding upon receiving COVID-19 mRNA vaccine ².

63 This is especially worrisome since infants are the children's age group most
64 affected by COVID-19 ^{3,4}. In view of the physiological alterations observed in
65 lactating women and of the crucial role of breastmilk in providing immunity to the
66 suckling infant, there is a pressing need to foresee how mRNA vaccines impact
67 immune responses in lactating mothers and to uncover the effector profile of
68 breast milk transferred immune protection.

69 Infants have an immature immune system and rely on the transfer of maternal
70 immune cells and antibodies via the breastmilk to provide them with immunity ⁵⁻
71 ⁹. Breastmilk humoral and cellular content changes during lactation, mirroring the
72 development of the infant's own immune system and digestive tract, but is
73 present in the milk during at least the first year of infant life ^{6,10,11}.

74 Human breastmilk contains a wide variety of immunoglobulins, including IgA
75 (~90%), IgM (~8%) and IgG (~2%) ¹². While human milk IgG mostly originates
76 from the blood, milk IgA and IgM originate from mucosa-associated lymphatic
77 tissue (MALT) ^{13,14}. At the mucosa sites, IgA and IgM are secreted in the form of
78 polymeric antibodies complexed to j-chain and secretory component proteins ¹³.

79 The secretory component plays a critical role in protecting SIgA and IgM from
80 proteolytic cleavage in the gut, facilitating their digestive traffic, systemic uptake
81 and tissue distribution in the infant ¹⁴. Importantly, neutralizing SIgA antibodies
82 elicited through maternal vaccination protect suckling infants from respiratory

83 disease upon transfer via breastmilk¹⁵. Few recent reports have documented IgA
84 presence in the breastmilk in response to COVID-19 mRNA vaccines¹⁶⁻²⁰.
85 Nonetheless, it remains to be addressed whether vaccine elicited milk IgA is
86 produced in the mammary mucosa in its secretory SIgA form or if it is provided
87 as monomeric IgA form by the blood. Moreover, it is currently unknown if vaccine
88 elicited milk IgA can confer immune protection to the infant through viral
89 neutralization.

90 In addition to antibodies, breast milk contains several types of maternal immune
91 cells, including B and T cells^{10,21,22}. Milk lymphocytes are more activated and/or
92 differentiated than their blood counterparts, with milk T cells comprising almost
93 exclusively of effector memory cells and with B cells containing mainly class-
94 switched IgD-memory B cells and plasma cells²³⁻²⁷. Several lines of evidence
95 support that milk B and T cells are capable of withstanding gastric environment
96²⁸⁻³⁰, enter blood circulation^{31,32} and be distributed into infant tissues^{33,34}. Recent
97 studies including human-based ones have indicated that transfer of maternal
98 lymphocytes via breast milk greatly assists the newborn's immune system¹⁴. It
99 has been previously shown that mRNA vaccines induce spike reactive B and T
100 cells in the blood^{35,36}. However, it remains to be addressed whether those
101 vaccines can elicit local mucosal T and B cell responses which could be
102 transferred to the suckling infant via breastmilk.

103 Prolactin, the hormone that promotes lactation, also functions as a cytokine
104 stimulating lymphocyte proliferation and cytokine production³⁷. Consequently,
105 prolactin drives a unique immune profile, composed by increased phagocytic and
106 cytolytic activities and B and T cell activation. A couple of recent studies have
107 shown that antibody production between lactating and non-lactating women

108 receiving COVID-19 mRNA vaccines is similar^{17,18}. Nonetheless, how the mRNA
109 vaccines impart on the cellular immune response of lactating women has so far
110 remained unaddressed.

111 Here we sought to gauge the effects of mRNA vaccines on the humoral and
112 cellular immune responses of breastfeeding women and to uncover breast milk
113 effector immune composition.

114

115 **Results**

116

117 **Milk and blood response to vaccine 1st dose are isotype discordant and** 118 **non-neutralizing**

119 We collected paired breastmilk and blood samples from 14 lactating, a median of
120 10 days after first (interquartile range (IQR), 8-12 days) and second (IQR, 9-10
121 days) Pfizer BNT162b2 mRNA vaccine administration. Infection by SARS-CoV-2
122 had not been reported in any of the study participants. Demographic data of the
123 study is contained in Tables S1 and S2.

124 We first looked at humoral response in the breastmilk and blood compartments
125 ~10 days post first vaccine dose, when protection conferred by BNT162b2 is
126 starting^{38,39}, by assessing IgG, IgA and IgM antibodies to SARS-CoV-2 trimeric
127 spike protein. All lactating women had anti-spike antibodies in circulation with
128 9/14 triple positive for IgG, IgA and IgM, 2/14 double positive for IgG and IgM,
129 2/14 single positive for IgG and 1/14 single positive for IgM (Fig. 1A; left graph,
130 orange). In contrast, 8/14 presented anti-spike antibodies in the breastmilk,
131 overwhelmingly of IgA isotype (8/8) with one donor having both IgG and IgA (Fig,
132 1A; right graph, purple). Anti-spike IgG and IgA antibody levels were higher in the
133 blood (Fig. 1B; orange) and did not correlate with donors' age (Fig. 1C).

134 Lactation stage affects breastmilk immune composition. Conversion from
135 colostrum (until 3-5 days after birth) to transitional milk (from day 3-5 to 2 weeks
136 postpartum) and finally to mature milk (from week 2 to the end of lactation) is
137 accompanied by a decrease in milk immune components. Nonetheless, mature
138 milk immune contents remain constant through the duration of lactation period ¹⁴.
139 Accordingly, in our cohort, composed exclusively by mature breastmilk samples,
140 milk IgA levels did not vary by breastfeeding duration (Fig. 1D). Interestingly, we
141 detected a trend between milk and blood anti-spike IgA levels (Fig. 1E).
142 Circulating and mucosal IgA are molecularly distinct. Whereas SIgA originated in
143 the mammary mucosa is secreted in its dimeric, trimeric or tetrameric forms,
144 blood IgA occurs as monomers ⁴⁰. As mRNA vaccines are better suited at
145 inducing systemic rather than mucosal immunity, we sought to identify the source
146 of IgA in the breast milk. To this end, we fractionated skim milk through size
147 exclusion chromatography and collected all fractions. Based on the calculated
148 molecular weight (MW) range for each peak (Fig. S1) and previous protein
149 profiles of human milk ⁴¹, oligomeric forms of SIgA (MW: 400-800 kDa) and
150 monomeric immunoglobulins (MW: 90-170 kDa) were expected to elute in peaks
151 O and M, respectively (Fig. 1F). We confirmed this by first running fractions O
152 and M together with non-fractionated milk on BN-PAGE (Fig. 1G). The protein
153 profile of non-fractionated milk is consistent with the protein profile observed on
154 the size exclusion chromatogram (Fig. 1 F, G). Fraction O shows a smeared band
155 above 720 kDa, likely corresponding to SIgA tetramers. Fraction M depicts a
156 single band at ~150 kDa, probably consisting of monomeric immunoglobulins.
157 The western blotting against human IgA corroborates the presence of IgAs in the
158 pre-purified sample and in fraction O, but not in fraction M (Fig. 1G). These data

159 exclude the possibility that milk spike-reactive IgA originates from the blood and
160 indicate that the ~150 kDa band visible in the native gel likely corresponds to IgG
161 (Fig. 1G). Finally, we verified that SIgA recognized both trimeric spike protein and
162 its RBD domain (Fig. 1H), confirming that anti-spike IgA antibodies are produced
163 by the mammary mucosa in the form of SIgA and not sourced from the blood.
164 Curiously, SIgA displayed higher reactivity towards trimeric spike than towards
165 its RBD domain, raising questions about its neutralization activity.

166 To gain insight into the possible neutralizing properties of milk and blood
167 antibodies, we first assessed their endpoint titers for the RBD domain ⁴². Milk
168 anti-RBD SIgA endpoint titers were lower when compared to blood IgA, IgG and
169 IgM (Fig. 1I). We next determined their virus-neutralizing activity through a
170 microneutralization assay using spike pseudotyped lentivirus infection of ACE-2
171 receptor expressing 293T cell line ⁴³. At 10d post vaccine prime, milk IgA had no
172 neutralizing activity (Fig. 1J; purple). Curiously, even though several blood
173 samples had moderate (1:450) and high (>1:1350) endpoint titers for IgG, IgA
174 and IgM, only one blood sample (1/14) displayed a weak neutralizing activity (Fig.
175 1 I, J).

176 Altogether our data shows that SIgA is produced early (d10) by the mammary
177 mucosa in response to the first dose of BNT162b2 vaccine. This early mammary
178 production of SIgA likely accounts for the distinct immunoglobulin composition
179 between the milk and blood compartments. Regardless, neither blood nor milk
180 antibodies possess neutralizing capacity at this point.

181

182 **SIgA in breastmilk remains non-neutralizing even after vaccine second**
183 **dose.**

184 While, circulating neutralizing IgG to BNT162b2 vaccine are optimally detected
185 after boost ⁴⁴, it is currently unknown whether vaccine induced milk antibodies
186 will provide neutralizing protection to the sucking infant ¹⁶⁻¹⁸. Contemporaneously
187 with IgG surge in the blood (Fig. 2 A, B; orange) at a median of 10 days after
188 vaccine second dose, we detected anti-spike and anti-RBD IgG (14/14), but not
189 IgM (0/14), in the milk (Fig. 2 A, B; purple). Interestingly, the frequency of milk
190 samples containing spike- and RBD-reactive SIgA was not altered (8/14), their
191 milk levels remained constant upon vaccine boost and did not correlate with
192 feeding duration (Fig. 2 A-C; purple). Similarly, circulating levels of IgA
193 recognizing spike protein remained unaltered by vaccine boost (Fig. 2A; orange).
194 However, circulating anti-RBD IgA levels were augmented after vaccine second
195 dose (Fig. 2B; orange).

196 Next, we wanted to know whether vaccine boost altered SIgA profile in the milk.
197 As before, we fractionated skim milk through size exclusion chromatography and
198 ascertained the composition of fractions O and M by western blot against human
199 IgA (Fig. 2D, E). As can be observed in the overlay of a paired sample, the size
200 exclusion chromatograms yield a similar profile after vaccine 1st and 2nd doses
201 (Fig. 2D), which was similarly observed for all the breastmilk samples (Fig. S2).
202 We compared SIgA reactivity to trimeric spike and its RBD domain after the
203 vaccination regimen by ELISA and found that there were no differences between
204 vaccine the first and second vaccine doses (Fig. 2 F, G). The fact that vaccine
205 boost has no effect in the milk levels of spike- and RBD-reactive SIgA, suggests
206 that SIgA production by the mammary mucosa in response to the vaccine is made
207 in a T cell-independent manner.

208 As expected, all the plasmas from fully vaccinated lactating HCW were
209 neutralizing (NT50: 231.24; IQR, 189.58–298.05) and comparable to an aged-
210 matched female HCW cohort (NT50: 315.54; IQR, 212.31–456.94) (Fig. 2 H, I)
211 and to previous reports for BNT162b2 vaccine^{36,44,45}. Importantly, regardless of
212 the increase in anti-spike SIgA tetramerization status none of the milk samples
213 displayed neutralizing activity, supporting the view that SIgA tetramerization
214 might be implicated in increasing target breadth rather than neutralization
215 activity⁴⁰.

216 In all, our data suggest that milk vaccine induced SIgA is likely produced in a T
217 cell independent manner. Moreover, spike- and RBD-reactive SIgA transferred
218 by the breast milk is unlikely to provide protection to the suckling infant through
219 SARS-CoV-2 neutralization.

220

221 **Lactating HCW have higher frequency of RBD-reactive memory B cells and** 222 **RBD-recognizing antibodies in circulation than controls**

223 While human IgA secreting B cells are retained in the mammary gland, functional
224 IgG secreting B cells can be transferred to the suckling infant via milk^{14,25,46}. We
225 sought to evaluate whether RBD-reactive B cells were present in the milk of
226 breastfeeding HCW after both the first and second vaccine doses. We were only
227 able to detect CD3⁻CD19⁺ B cells in 5 out of 14 milk samples (Fig 3 A, B).
228 Consistent with previous report²⁵, milk B cells were overwhelming IgD⁻ illustrating
229 that they had undergone class-switch (Fig 3A). Due the limited number of B cells
230 detected we were not able to assess the presence of RBD-reactive milk B cells.
231 Mainly due to hormonal changes, lactating women display distinct immune
232 responses³⁷. To fully evaluate the B cell immune response to BNT162b2 vaccine

233 in this population, we determined the frequency of antibody secreting RBD-
234 reactive plasmablasts and memory B cells (Fig 3 B, C). A clear population of
235 RBD-binding IgD⁻ B cell population could be detected at ~10 days post vaccine
236 first dose (Fig 3 B, C; prime), whose frequency (~1.7%) remained unaltered upon
237 vaccine boost (Fig 3 B, C; boost). We then analyzed the frequency of RBD-
238 reactive plasmablasts and memory B cells. Both RBD-reactive plasmablasts and
239 memory B cells were detectable after vaccine prime (Fig. 3 B, C). Upon vaccine
240 boost, only plasmablasts appear to increase in frequency (Fig. 3 B, C). Curiously,
241 when compared to age- and gender-matched controls, in breastfeeding HCW the
242 effector B cell response to RBD was skewed toward memory B cells with
243 concomitant decrease in short-lived plasmablasts (Fig. 3C). Memory B cells have
244 been proposed to play a key role in mounting recall responses to COVID-19
245 mRNA vaccines ⁴⁴. Accordingly, breastfeeding HCW registered higher titers of
246 circulating RBD-reactive IgG and IgA antibodies than controls (Fig. 3D). Finally,
247 we found no correlation between the frequency of RBD-reactive total B cells or
248 RBD-reactive memory B cells and spike/RBD-reactive IgG levels or with
249 neutralization titers (Fig. 3 E, F).

250 Although we were not able to detect RBD-reactive B cells, we found that lactating
251 HCW had higher frequencies of RBD-reactive circulating memory B cells and
252 higher RBD-IgG antibodies, when compared to controls.

253

254 **Spike-specific T cells are transferred through breastmilk after vaccine**
255 **boost.**

256 Emerging evidence suggests the requirement of both antibody-mediated and T
257 cell-mediated immunity for effective protection against SARS-CoV-2 ^{47,48}.

258 Importantly, these mammary gland T cells are transferred through the milk to the
259 nursing infant and mediate immune protection ^{27,49}.

260 To detect trimeric spike specific CD4⁺ T cells in the milk and in circulation, we
261 used an Activation Induced Marker (AIM) assay using OX40 and CD25 dual
262 expression to detect spike reactivity ⁵⁰⁻⁵². Out of 14 breastfeeding HCW, we could
263 only robustly detect CD4⁺ T cells in the milk of 5 donors. After vaccine second
264 dose, spike-reactive OX40⁺CD25⁺CD4⁺ T cells could be detected in 100% of milk
265 samples with detectable CD4⁺ T cells (Fig. 4 A, B). Suggesting that in addition to
266 non-neutralizing antibodies, spike-reactive CD4⁺ T cells are transferred through
267 the breastmilk, upon mRNA vaccination.

268 All breastfeeding vaccinated HCW possessed spike reactive OX40⁺CD25⁺CD4⁺
269 T cells (median, 0.71%; IQR, 0.38–1.07) in circulation right after vaccine prime,
270 and their frequency was not altered by subsequent boost (Fig 4 B, C), even
271 though their activation state measured by CD69 expression decreased with
272 vaccine boost (Fig. 4 B, C). Curiously, it appears that after vaccine boost
273 breastfeeding HCW tended to have less spike-reactive CD4⁺ T cells when
274 compared to vaccinated controls (Fig. 4C). In view of the role of CD4⁺ T cells in
275 B cell effector differentiation, we looked if there was an association between
276 circulating spike-reactive T cells and RBD-reactive plasmablasts and memory B
277 cells. There was no correlation between spike-reactive T cells and RBD-reactive
278 plasmablasts or memory B cells (Fig. 4D).

279 All together these data show that in addition to non-neutralizing antibodies, milk
280 also transfers spike-reactive T cells. The fact that spike-reactive T cells are only
281 detectable in the milk after vaccine boost, reinforces the view that spike/RBD-

282 sIgA, detected in the milk as early as 10 days post vaccine first dose, are likely
283 the result of T-cell independent production.

284

285 **Discussion**

286 Recent data from Brazil has brought to the forefront that within the pediatric
287 population, infants are among the most susceptible to and present the highest
288 COVID-19 fatality rate ^{3,4,53}. Yet, lactating women were excluded from initial
289 vaccine trials and lactating HCW were often advised by national health authorities
290 to discontinue breastfeeding upon receiving COVID-19 mRNA vaccine ². Evolved
291 to provide immunity to the suckling infant, lactating women display a unique
292 immune activation state. How mRNA vaccines impact this distinct immune state
293 and which is the breadth and effector profile of milk transferred immune response
294 remains poorly understood. Through a combination of serology, virus
295 neutralization assays and size exclusion chromatography we identified, to the
296 best of our knowledge for the first time, the secretory and neutralizing properties
297 of breastmilk transferred antibodies and cellular immunity following BNT162b2
298 vaccination. Moreover, we immunophenotyped the B and T cell responses to the
299 vaccine in the milk and blood of lactating women. All together, these findings
300 indicate that a possible immune protection conferred by breastmilk will occur in a
301 neutralization-independent T cell-dependent fashion. In addition, the higher
302 frequency in RBD-memory B cells in lactating women raise the possibility of
303 increased duration of vaccine conferred immune protection.

304 A dramatic plunge of COVID-19 cases starts as early as 12 days after BNT162b2
305 first vaccine dose ^{38,39}. We found that early vaccine immune response in the blood
306 and in the breastmilk was isotype discordant. Whereas, breastmilk contained

307 exclusively low titers of spike-reactive IgA, circulating anti-spike antibodies
308 spanned from low to high titers and through IgG, IgA, and IgM isotypes. These
309 results highlight the functional compartmentalization between mucosal and the
310 systemic immunity and the limitations of systemic administered BNT162b2
311 vaccine in eliciting a strong mucosal response ⁵⁴. The function of antibodies
312 produced within the mammary gland MALT is to provide protective immunity to
313 the suckling infant through the secretion of polymeric antibodies complexed to j-
314 chain and secretory component proteins ¹³. The secretory component is essential
315 to ensure that milk antibodies are effectively transferred via the breastmilk by
316 providing protection from proteolytic cleavage and by facilitating systemic uptake
317 and tissue distribution in the infant ¹³. Spike-reactive SIgA were detected in the
318 breast milk of COVID-19 patients ⁵⁵, nonetheless whether SIgA was similarly
319 present in the breast milk upon mRNA vaccination had remained unaddressed.
320 By combining size exclusion chromatography with customized spike-ELISA, we
321 concluded that vaccination does in fact originate spike-reactive SIgA, which is
322 secreted predominately as tetramers. We detected SIgA in 57% of milk samples.
323 Our detected milk SIgA prevalence is on the lower-end of the interval of milk IgA
324 prevalence (61.8% to >80%) detected by others ¹⁶⁻²⁰. This discrepancy can
325 probably be ascribed to different experimental procedures. While we detected
326 SIgA in milk samples that had been diluted 50-fold, these previous works either
327 used undiluted milk samples or diluted them at a maximum of 5-fold.
328 Upon administration of influenza vaccine to pregnant women, neutralizing
329 influenza-specific IgA are effectively transferred to breast milk ¹⁵. Whether mRNA
330 vaccines similarly promote the transfer of neutralizing spike-specific IgA to
331 breastmilk has remained unexplored. Our data elucidate that upon vaccination of

332 lactating women with BNT162b2, milk secreted spike-reactive SIgA is non-
333 neutralizing. This is in great contrast with COVID-19 infection, where neutralizing
334 IgA occurs in the milk of infected lactating women ⁵⁶. This is likely due to the fact
335 that SARS-CoV-2 infection effectively primes airway and gut mucosa immunity,
336 while the vaccine is defective in providing mucosal immunity. In fact, mucosal IgA
337 secretion has been shown to play an important role in the early control of SARS-
338 CoV-2 infection ⁵⁷ and a recent paper has shown that SIgA dimers cloned from
339 COVID-19 patients display a 7-fold higher neutralization capacity when compared
340 to IgG ⁵⁸. Importantly, our results show that spike-reactive SIgA titers are not
341 altered by vaccine second dose and that its presence in the milk precedes the
342 detection of spike-T cells, strongly suggesting that spike-reactive SIgA is
343 produced in a T cell-independent manner. T cell-independent IgA responses
344 result in the production of low affinity and polyreactive antibodies ⁵⁹, which could
345 help explain the absence of neutralizing function. Moreover, BNT162b2 induced
346 circulating IgA has been proposed to be produced also in a T-cell independent
347 manner ⁶⁰. Nevertheless, milk transferred spike-reactive SIgA could be conferring
348 protection through non-neutralizing actions, namely through Fc-related functions
349 such as antibody dependent cytotoxicity, complement activation and
350 phagocytosis.

351 An important and until now completely unexplored route for milk transferred
352 immunity is through T cells. Previous studies have shown that milk transferred
353 lymphocytes can survive the adverse environment of the digestive tract and seed
354 in the infant's tissues ³⁰⁻³⁶. This is due to a combination of a biochemical reaction
355 between infant's saliva and breast milk that protects lymphocytes from acid injury
356 ⁵⁻⁷, a decrease in enzyme and acid content in the infant's digestive tract ^{61,62}, and

357 an increase in gut permeability³¹. Despite the strong experimental support that
358 mRNA vaccine induced CD4⁺ T cells might play an important role in mediating
359 protection^{45,63,64} especially in suboptimal neutralizing antibodies settings⁶⁵, this
360 is, to the best of our knowledge, the first report to detect spike-reactive T cells in
361 the breast milk of vaccinated mothers. It is possible that milk transferred spike-
362 reactive T cells might mediate protective function by seeding in the infant's upper
363 respiratory tract and gut. We found that spike-reactive T cells accounted for
364 ~3.5% of milk CD4⁺ T cells. Even though this frequency might seem low, it is
365 worth to have in mind that a suckling infant ingest large volumes of milk daily,
366 which implies the ingestion of significant quantities of spike-reactive T cells.

367 Prolactin, the hormone that induces milk production also functions as a cytokine
368 that plays an important role in immune activation³⁷. Since breastfeeding women
369 were excluded from initial vaccine trials, we sought to compare their response to
370 BNT162b2 vaccine. We detected higher RBD-reactive IgG and IgA titers in
371 lactating women, nonetheless their neutralization titers were undistinguishable
372 from controls. These results are consistent with previous findings^{17,18}. In addition,
373 we found that lactating women had higher frequencies of RBD-reactive memory
374 B cells but lower frequencies of plasmablasts in circulation. Suggesting that the
375 immune response to the vaccine in lactating women might be veered toward
376 longer lasting memory in detriment of short-lived antibody production. Further
377 studies will be needed to determine if these cellular differences are maintained in
378 medium term and whether they will impact long term protection.

379 Here we show that upon BNT162b2 vaccination immune transfer to the
380 breastmilk does not involve neutralizing antibodies. In fact, milk transferred T
381 cells together with non-neutralizing antibodies might play an important role in

382 mediating protection to SARS-CoV-2 infection in the infant. Our data also support
383 the view that lactating women immune responses to the vaccine are qualitatively
384 different and veered toward long-lasting memory B cell response, despite
385 displaying equivalent neutralization antibody titers. It is worth mentioning that the
386 results obtained represent only a snapshot of what is likely a dynamic immune
387 response, using a small cohort. Future works using a larger sample size and
388 longitudinal design are needed to determine whether the non-neutralizing
389 antibodies and T cells contained in the breastmilk following BNT162b2
390 vaccination transfer immunity to the suckling infant and to elucidate their effector
391 mechanisms.

392

393 **Figure Legends**

394 **Figure 1- Early response to vaccine 1st dose in the milk and in the blood are**
395 **isotype discordant and non-neutralizing.**

396 (A) Levels of IgG, IgA and IgM against SARS-CoV-2 trimeric spike protein in the
397 plasma (left graph; orange) and skim milk (right graph: purple) diluted at 1:50 in
398 breastfeeding HCW (n=14) at ~10 days post first dose of BNT162b2 mRNA
399 vaccine, measured by absorbance at 450 nm (OD_{450}). Dashed line indicates
400 assay cut off.

401 (B) Donor matched analysis of OD_{450} values for IgG and IgA in plasma (orange)
402 and in skim milk (purple) diluted at 1:50.

403 (C) Correlation between blood IgG, IgA and IgM levels and donor's age in years.

404 (D) Correlation between milk IgA recognizing trimeric spike protein after the first
405 vaccine dose and feeding duration in months.

406 (E) Correlation between trimeric spike reactive IgA in the plasma versus skim
407 milk.

408 (F) Illustrative size exclusion chromatogram of skim milk. Two fractions,
409 designated O and M, suspected to correspond to oligomeric SIgA and monomeric
410 immunoglobulins, were collected.

411 (G) Unfractionated skim milk (Pre Pur) together with fractions O and M, suspected
412 to correspond to oligomeric SIgA and monomeric immunoglobulins, and
413 unfractionated serum sample from a COVID-19 patient (COVID+) were analysed
414 through Blue Native PAGE (left) and α -IgA western blotting (right).

415 (H) OD₄₅₀ values of size exclusion chromatography purified SIgA recognizing
416 trimeric spike protein or its RBD domain.

417 (I) Endpoint titers for skim milk IgA (purple) and plasma IgG, IgA and IgM (orange)
418 recognizing spike RBD domain.

419 (J) Neutralization curves for plasma (orange) and skim milk (purple) for SARS-
420 CoV-2 pseudotyped virus.

421 p values determined by ANOVA, post-hoc Turkey's and Friedman, post-hoc
422 Dunn's when comparing 3 groups. p values determined by parametric paired *t*
423 test and by non-parametric paired Wilcoxon test when appropriate. Pearson
424 correlation was used for parametric data and Spearman correlation for non-
425 parametric data. ***p<0.001, **p<0.01, *p<0.05, ns = not significant.

426

427 **Figure 2- Neutralizing antibodies are found in the blood but not in the milk**
428 **after vaccine second dose.**

429 (A) Comparison of IgG, IgA and IgM, recognizing trimeric spike protein, at
430 median of 10 days after the first (prime) and median of 10 days after the second
431 (boost) of BNT162b2 vaccine in the plasma (orange) and in skim milk (purple)

432 diluted at 1:50, measured by absorbance at 450 nm (OD₄₅₀). Dashed line
433 indicates test cut off.

434 (B) Comparison of IgG, IgA and IgM, recognizing spike RBD domain, performed
435 as in (A). Dashed line indicates test cut off.

436 (C) Correlation between milk IgG (left) and IgA (right) recognizing trimeric spike
437 protein and feeding duration in months.

438 (D) Illustrative size exclusion chromatogram of a skim milk samples from the
439 second (red) and first (blue) doses. Two fractions, designated O and M,
440 suspected to correspond to oligomeric SIgA and monomeric immunoglobulins,
441 were collected.

442 (E) Unfractionated skim milk (Pre Pur) together with fractions O and M, suspected
443 to correspond to oligomeric SIgA, respectively, were analysed through Blue
444 Native PAGE (left) and α -IgA western blotting (right).

445 (F, G) Comparison between the OD₄₅₀ values of SEC-purified SIgA recognizing
446 trimeric spike protein (F) or its RBD domain (G) after the first (prime) and second
447 (boost) vaccine doses.

448 (H) Neutralization curves for plasma (orange) and skim milk (purple) for SARS-
449 CoV-2 pseudotyped virus.

450 (I) Neutralization titers (NT₅₀) for SARS-CoV-2 pseudotyped virus in the plasma
451 of nursing (orange) and non-breastfeeding (control; grey) HCW.

452 p values determined by parametric paired *t* test and by non-parametric paired
453 Wilcoxon test when appropriate. For unpaired data, Man-Whitney test was used
454 when appropriate. Spearman correlation was used for correlative analysis.

455 *****p*<0.0001, ****p*<0.001, ***p*<0.01, **p*<0.05, ns = not significant.

456

457 **Figure 3- Lactating HCW have higher frequency of RBD-reactive memory B**
458 **cells and RBD-recognizing antibodies in circulation than controls.**

459 (A) Gating strategy for CD3⁻CD19⁺IgD⁻ in the milk, after first (prime) and second
460 (boost) doses of BNT162b2 vaccine in breastfeeding HCW.

461 (B) Gating strategy for circulating RBD-reactive CD3⁻CD19⁺IgD⁻CD20⁻CD27⁺
462 plasmablasts and CD3⁻CD19⁺IgD⁻CD20⁺CD27⁺ memory B cells.

463 (C) Cumulative frequency of circulating CD3⁻CD19⁺ (top left) total B cells, RBD
464 reactive CD3⁻CD19⁺IgD⁻ B cells (top right), CD3⁻CD19⁺IgD⁻CD20⁻CD27⁺
465 plasmablasts (bottom left) and CD3⁻CD19⁺IgD⁻CD20⁺CD27⁺ memory B cells
466 (bottom right) after first (prime) and second (boost) vaccine doses for nursing
467 (orange) and after the second (boost) vaccine dose for non-breastfeeding
468 (control; grey).

469 (D) Endpoint titers for RBD-specific IgG, IgA and IgM from skim milk (purple) and
470 plasma (orange) of nursing and from plasma (grey) of non-breastfeeding (control;
471 grey) HCW. nd = non-detectable

472 (E) Correlation between spike-specific IgG (left), RBD-specific IgG (middle), and
473 neutralization titers (right; NT50) and the frequency of RBD-reactive CD3⁻
474 CD19⁺IgD⁻ B cells, upon vaccine boosting.

475 (F) Correlation between spike-specific IgG (left), RBD-specific IgG (middle), and
476 neutralization titers (right; NT50) and the frequency of RBD-reactive CD3⁻
477 CD19⁺IgD⁻CD20⁺CD27⁺ memory B cells, upon vaccine boosting.

478 p values determined by parametric paired *t* test and by non-parametric paired
479 Wilcoxon test when appropriate. For unpaired data, *t* test was used for parametric
480 data and Man-Whitney test was used for non-parametric data when appropriate.

481 Spearman correlation was used for correlative analysis. *** $p < 0.001$, ** $p < 0.01$, *
482 $p < 0.05$, ns = not significant.

483

484 **Figure 4- Spike-specific T cells are transferred through breastmilk after**
485 **vaccine boost.**

486 (A) Gating strategy for CD3⁺CD4⁺OX40⁺CD25⁺ spike specific T cells in the milk,
487 after first (prime) and second (boost) doses of BNT162b2 vaccine in
488 breastfeeding HCW.

489 (B) Gating strategy of circulating CD3⁺CD4⁺OX40⁺CD25⁺ spike specific T cells,
490 after first (prime) and second (boost) doses of BNT162b2 vaccine in
491 breastfeeding HCW.

492 (C) Cumulative frequency of CD3⁺CD4⁺ (left), CD3⁺CD4⁺OX40⁺CD25⁺ (middle)
493 and of CD3⁺CD4⁺OX40⁺CD25⁺CD69⁺ (right) circulating T cells after first (prime)
494 and second (boost) vaccine doses for nursing (orange) and after the second
495 (boost) vaccine dose for non-breastfeeding (control; grey).

496 (D) Correlation between the frequency of RBD-reactive CD3⁻CD19⁺IgD⁻
497 CD20⁺CD27⁺ memory B cells (right) and RBD-reactive CD3⁻CD19⁺IgD⁻CD20⁻
498 CD27⁺ plasmablasts cells (left) with the frequency of CD3⁺CD4⁺OX40⁺CD25⁺
499 circulating T cells after second vaccine dose.

500 p values determined by parametric paired t test and by non-parametric paired
501 Wilcoxon test when appropriate. For unpaired data, t test was used for parametric
502 data and Man-Whitney test was used for non-parametric data when appropriate.

503 Pearson correlation was used for correlative analysis. *** $p < 0.001$, * $p < 0.05$, ns =
504 not significant.

505

506

507 **Supplemental Figure Legends**

508 **Figure S1- Standardization of molecular weight range of the** 509 **chromatographic separation.**

510 (A) Chromatogram of all standard proteins run in a Superdex 200 increase 10/300
511 GL. HWM Filtration Calibration Kit (Cytiva) were used with the following proteins:
512 thyroglobulin (669 kDa); ferritin (450 kDa), aldolase (158 kDa), conalbumin (75
513 kDa) and ovalbumin (44 kDa). These standard proteins were dissolved in bi-
514 distilled water and their chromatographic profiles were obtained using an UV
515 detector.

516 (B) Graphical representation of calibration curve of partition coefficient (K_{av}) of
517 each protein versus their respective molecular weight in Daltons. The K_{av} was
518 calculated through the following formula: $K_{av} = (V_e - V_0) / (V_c - V_0)$ where V_e is the
519 elution volume of the protein, V_0 is the void volume and V_c is the column bed
520 volume. A dispersion graph K_{av} vs $\log MW$ was constructed. The equation
521 obtained for the calibration curve is: $K_{av} = -0.322 \log(MW) + 1.9436$, where K_{av}
522 is the partition coefficient and MW is the protein molecular weight (Da).

523

524 **Figure S2- Size-exclusion chromatograms of breastmilk samples** 525 **(Superdex 200 Increase 10/300 GL).**

526 (A) SEC- chromatograms of all breastmilk samples from first and second vaccine
527 doses superposed.

528

529 **Acknowledgements**

530 We are very grateful to all the participants of the study. We
531 thank Cláudia Andrade at CEDOC Flow Cytometry platform for technical support.

532 This work was supported by ESCMID and by Gilead Génese (PGG/009/2017)
533 grants to HS, RESEARCH4COVID 19 (Ref 580) to MJA, EU H2020 projects No.
534 823780 and 871037 (iNEXT-Discovery) to MA, and by Fundação para a Ciência
535 e Tecnologia (FCT) through Project MOSTMICRO-ITQB with refs
536 UIDB/04612/2020 and UIDP/04612/2020 to MA and DA. JG, DA, MJA HS are
537 supported by Fundação para a Ciência e Tecnologia (FCT) through
538 PD/BD/128343/2017, BD/147987/2019, CEECIND/02373/2020 and
539 CEECIND/01049/2020, respectively. Graphical abstract was created with
540 BioRender.com.

541
542
543

Author contributions

544 JG, AMJ, MA, DA, FF designed and performed experiments and analyzed the
545 data. NC and FS enrolled the subjects and collected clinical data. MJA and MA
546 provided critical expertise and insights. HS conceptualized the study, designed
547 experiments, analyzed the data, supervised the project and wrote
548 the manuscript. All authors discussed the results and commented on the
549 manuscript.

550
551

Competing interests

552 The authors declare no competing interests.

553
554

STAR METHODS

Study participants and human samples

556 Blood and breastmilk from 14 nursing mothers were collected between day 7 and
557 16 and between day 7 and 13 post-immunization with Pfizer BTN162b2 mRNA
558 vaccine (Table S1). Blood from controls was collected between day 10 and 16

559 after vaccine second dose (Table S2). Blood was collected by venipuncture in
560 EDTA tubes and breastmilk was collected with breast pump into sterile
561 containers. Both biospecimens were immediately processed. All participants
562 provided informed consent and all procedures were approved by NOVA Medical
563 School ethics committee, in accordance with the provisions of the Declaration of
564 Helsinki and the Good Clinical Practice guidelines of the International Conference
565 on Harmonization.

566

567 **Peripheral blood and breastmilk cell isolation**

568 Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient
569 centrifugation (Biocoll, Merck Millipore). Breast milk cells were isolated by
570 centrifugation. Plasma and skim milk were respectively stored at -80°C or -20°C
571 until further analysis. PBMCs and breastmilk mononuclear cells were suspended
572 in freezing media (10% DMSO in FBS) and stored at -80°C until subsequent
573 analysis.

574

575 **Flow cytometry for detection of SARS-CoV-2 reactive B and T cells**

576 RBD was labelled with an available commercial kit according to manufacturer's
577 instructions (life technologies, A20181). For detection of SARS-CoV-2 reactive T
578 cells, cryopreserved PBMCs were rested for 1h at 37°C and then stimulated
579 overnight with either 1 mg/mL of spike protein plus 5 µg/mL of anti-CD28
580 (CD28.2) (BioLegend) cross-linked with 2.5 µg/mL of anti-mouse IgG1 (RMG1-1)
581 (BioLegend) or with medium alone (negative control). PBMCs were stained with
582 a fixable viability dye eFluor™ 506 (invitrogen) and surface labelled with the
583 following antibodies all from BioLegend: anti-CD3 (UCHT1), anti-CD4 (SK3), anti-
584 OX40 (Ber-ACT35), anti-CD25 (M-A251), anti-CD69 (FN50), anti-CXCR-5

585 (J252D4), anti-CCR6 (G034E3), anti-CD19 (SJ25C1), anti-IgD (IA6-2), anti-
586 CD27 (O323) and anti-CD20 (2H7) and also with the RBD labelling as described
587 above. Cells were washed, fixed with 1% PFA and acquired in BD FACS Aria III
588 equipment (BD Biosciences) and analysed with FlowJo v10.7.3 software (Tree
589 Star).

590

591 **ELISA**

592 Antibody binding to SARS-CoV-2 trimeric spike protein or its RBD domain was
593 assessed by a previously described in-house ELISA assay ⁴² based on the
594 protocol by Stadlbauer et al ⁶⁶. Briefly, 96-well plates (Nunc) were coated
595 overnight at 4°C with 0.5 µg/ml of trimeric spike or RBD. After blocking with 3%
596 BSA diluted in 0.05% PBS-T, serially diluted plasma samples were added and
597 incubated for 1 h at room temperature. Plates were washed and incubated for
598 30 min at room temperature with 1:25,000 dilution of HRP-conjugated anti-human
599 IgA, IgG and IgM antibodies (Abcam, ab97225/ab97215/ab97205) goat anti-
600 human IgA/IgG/IgM-HRP secondary antibodies (diluted at in 1% BSA- 0.05%
601 PBS-T. Plates were washed and incubated with TMB substrate (BioLegend),
602 stopped by adding phosphoric acid (Sigma) and read at 450nm. Endpoint titers
603 were defined as the last dilution before the absorbance dropped below OD₄₅₀ of
604 0.15. This value was established using plasma from pre-pandemic samples
605 collected from subjects not exposed to SARS-CoV-2 ⁴². For samples that
606 exceeded an OD₄₅₀ of 0.15 at last dilution (1:10,9350), end-point titer was
607 determined by interpolation ⁶⁷. As previously described ⁴², in each assay we used
608 6 internal calibrators from 2 high-, 2 medium- and 2 low-antibody producers that
609 has been diagnosed for COVID-19 through RT-PCR of nasopharyngeal and/or

610 oropharyngeal swabs. As negative controls, we used pre-pandemic plasma
611 samples collected prior to July 2019.

612

613 **Sample purification by size exclusion chromatography (SEC)**

614 Skim milk samples were centrifuged at 20,000x *g*, for 5 min at 4°C, to remove
615 precipitates or debris prior to SEC. A volume of 200 µL of each clarified sample
616 was injected on a Superose 200 increase 10/300 GL column coupled to an AKTA
617 pure FPLC system (Cytiva) with UV/Visible detector at 280 nm. PBS at pH 7.4
618 was used as elution buffer with a flow rate of 0.5 mL/min. A similar procedure
619 was applied to a sample of blood serum from a COVID-19 positive patient to
620 serve as control. Fractions of 0.5 mL were collected and gathered according to
621 the peaks identified in the chromatogram to be analysed on blue native
622 polyacrylamide gel electrophoresis (BN-PAGE) on NativePAGE 4–16% Bis-Tris
623 gels (ThermoFisher Scientific) with NativeMark (ThermoFisher Scientific) as
624 molecular weight marker and stained with ProBlue Safe Stain (Giotto Biotech).
625 Western blots (WB) were performed using nitrocellulose membranes for gel
626 transfer and goat anti-human IgA alpha chain (HRP) (Abcam) with SuperSignal™
627 West Pico Chemiluminescent Substrate (ThermoFischer Scientific) for antibody
628 detection, in Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, Inc).

629

630 **Production of 293T cells stably expressing human ACE2 receptor**

631 Production of 293T cells stably expressing human ACE2 receptor was done as
632 previously described ⁴³. Briefly, VSV-G pseudotyped lentiviruses encoding
633 human ACE2, 293ET cells were transfected with pVSV-G, psPAX2 and pLEX-
634 ACE2 using jetPRIME (Polyplus), according to manufacturer's instructions.

635 Lentiviral particles in the supernatant were collected after 3 days and were used
636 to transduce 293T cells. Three days after transduction, puromycin (Merck,
637 540411) was added to the medium, to a final concentration of 2.5 µg/ml, to select
638 for infected cells. Puromycin selection was maintained until all cells in the control
639 plate died and then reduced to half. The 293T-Ace2 cell line was passaged six
640 times before use and kept in culture medium supplemented with 1.25 µg/ml
641 puromycin.

642

643 **Production and titration of spike pseudotyped lentiviral particles**

644 To generate spike pseudotyped lentiviral particles, 6×10^6 293ET cells were co-
645 transfected with 8.89 µg pLex-GFP reporter, 6.67 µg psPAX2, and 4.44 µg
646 pCAGGS-SARS-CoV-2-S_{trunc} D614G, using jetPRIME according to
647 manufacturer's instructions. The virus-containing supernatant was collected after
648 3 days, concentrated 10 to 20-fold using Lenti-X™ Concentrator (Takara,
649 631231), aliquoted and stored at -80°C. Pseudovirus stocks were titrated by serial
650 dilution and transduction of 293T-Ace2 cells. At 24h post transduction, the
651 percentage of GFP positive cells was determined by flow cytometry, and the
652 number of transduction units per mL was calculated.

653

654 **Neutralization assay**

655 Heat-inactivated skim breast milk and plasma samples were four-fold serially
656 diluted and then incubated with spike pseudotyped lentiviral particles for 1h at
657 37°C. The mix was added to a pre-seeded plate of 293T-Ace2 cells, with a final
658 MOI of 0.2. At 48h post-transduction, the fluorescent signal was measured using
659 the GloMax Explorer System (Promega). The relative fluorescence units were

660 normalized to those derived from the virus control wells (cells infected in the
661 absence of plasma or skim breast milk), after subtraction of the background in
662 the control groups with cells only.

663

664 **Statistical analysis**

665 The half-maximal neutralization titre (NT₅₀), defined as the reciprocal of the
666 dilution at which infection was decreased by 50%, was determined using four-
667 parameter nonlinear regression (least squares regression without weighting;
668 constraints: bottom=0) (GraphPad Prism 9). The nonparametric Wilcoxon test
669 (paired) and Man-Whitney test (unpaired) and the parametric *t* test (paired and
670 unpaired) were used as described in figure legends. Spearman and Pearson
671 correlation test were used in correlation analysis. ANOVA with post-hoc Turkey's
672 multiple comparison test and Friedman with post-hoc Dunn's multiple comparison
673 test were used to compare means between groups.

674

675 **References**

676

- 677 1. Riley, L. E. & Jamieson, D. J. Inclusion of Pregnant and Lactating Persons in
678 COVID-19 Vaccination Efforts. *Ann Intern Med* (2021). doi:10.7326/M21-0173
- 679 2. Merewood, A., Bode, L., Davanzo, R. & Perez-Escamilla, R. Breastfeed or be
680 vaccinated—“an unreasonable default recommendation. *The Lancet* **397**, 578
681 (2021).
- 682 3. de Siqueira Alves Lopes, A. *et al.* Coronavirus disease-19 deaths among children
683 and adolescents in an area of Northeast, Brazil: why so many? *Tropical Medicine &*
684 *International Health* **26**, 115–119 (2021).
- 685 4. Dong, Y. *et al.* Epidemiology of COVID-19 Among Children in China. *Pediatrics* **145**,
686 (2020).
- 687 5. Ghosh, M. K., Nguyen, V., Muller, H. K. & Walker, A. M. Maternal Milk T Cells Drive
688 Development of Transgenerational Th1 Immunity in Offspring Thymus. *J. Immunol.*
689 **197**, 2290–2296 (2016).
- 690 6. Cabinian, A. *et al.* Transfer of Maternal Immune Cells by Breastfeeding: Maternal
691 Cytotoxic T Lymphocytes Present in Breast Milk Localize in the Peyer's Patches of
692 the Nursed Infant. *PLoS ONE* **11**, e0156762 (2016).
- 693 7. Arvola, M. *et al.* Immunoglobulin-secreting cells of maternal origin can be detected
694 in B cell-deficient mice. *Biol Reprod* **63**, 1817–1824 (2000).
- 695 8. Schlesinger, J. J. & Covelli, H. D. Evidence for transmission of lymphocyte
696 responses to tuberculin by breast-feeding. *The Lancet* **2**, 529–532 (1977).

- 697 9. Ohsaki, A. *et al.* Maternal IgG immune complexes induce food allergen-specific
698 tolerance in offspring. *J Exp Med* **215**, 91–113 (2018).
- 699 10. Trend, S. *et al.* Leukocyte Populations in Human Preterm and Term Breast Milk
700 Identified by Multicolour Flow Cytometry. *PLoS ONE* **10**, e0135580 (2015).
- 701 11. Goldman, A. S., Garza, C., Nichols, B. L. & Goldblum, R. M. Immunologic factors in
702 human milk during the first year of lactation. *The Journal of Pediatrics* **100**, 563–567
703 (1982).
- 704 12. Goldsmith, S. J., Dickson, J. S., Barnhart, H. M., Toledo, R. T. & Eiten-Miller, R. R.
705 IgA, IgG, IgM and Lactoferrin Contents of Human Milk During Early Lactation and
706 the Effect of Processing and Storage. *J Food Prot* **46**, 4–7 (1983).
- 707 13. Brandtzaeg, P. Induction of secretory immunity and memory at mucosal surfaces.
708 *Vaccine* **25**, 5467–5484 (2007).
- 709 14. Laouar, A. Maternal Leukocytes and Infant Immune Programming during
710 Breastfeeding. *Trends Immunol.* **41**, 225–239 (2020).
- 711 15. Schlaudecker, E. P. *et al.* IgA and neutralizing antibodies to influenza A virus in
712 human milk: a randomized trial of antenatal influenza immunization. *PLoS ONE* **8**,
713 e70867 (2013).
- 714 16. Perl, S. H. *et al.* SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19
715 Vaccination of Breastfeeding Women. *JAMA* (2021). doi:10.1001/jama.2021.5782
- 716 17. Atyeo, C. *et al.* COVID-19 mRNA vaccines drive differential Fc-functional profiles in
717 pregnant, lactating, and non-pregnant women. *bioRxiv* 2021.04.04.438404 (2021).
718 doi:10.1101/2021.04.04.438404
- 719 18. Gray, K. J. *et al.* COVID-19 vaccine response in pregnant and lactating women: a
720 cohort study. *medRxiv* 2021.03.07.21253094 (2021).
721 doi:10.1101/2021.03.07.21253094
- 722 19. Baird, J. K., Jensen, S. M., Urba, W., Fox, B. A. & Baird, J. R. SARS-CoV-2
723 antibodies detected in human breast milk postvaccination. *MedRxiv* (2021).
724 doi:10.1101/2021.02.23.21252328v1
- 725 20. Golan, Y. *et al.* Immune response during lactation after anti-SARS-CoV2 mRNA
726 vaccine. *medRxiv* 2021.03.09.21253241 (2021). doi:10.1101/2021.03.09.21253241
- 727 21. Bedin, A.-S. *et al.* MAIT cells, TCR $\gamma\delta^+$ cells and ILCs cells in human breast milk
728 and blood from HIV infected and uninfected women. *Pediatr Allergy Immunol* **30**,
729 479–487 (2019).
- 730 22. Hassiotou, F. & Geddes, D. T. Immune cell-mediated protection of the mammary
731 gland and the infant during breastfeeding. *Adv Nutr* **6**, 267–275 (2015).
- 732 23. Bertotto, A. *et al.* Human breast milk T lymphocytes display the phenotype and
733 functional characteristics of memory T cells. *Eur. J. Immunol.* **20**, 1877–1880
734 (1990).
- 735 24. Sabbaj, S. *et al.* Breast milk-derived antigen-specific CD8⁺ T cells: an
736 extralymphoid effector memory cell population in humans. *J.I.* **174**, 2951–2956
737 (2005).
- 738 25. Tuailon, E. *et al.* Human Milk-Derived B Cells: A Highly Activated Switched Memory
739 Cell Population Primed to Secrete Antibodies. *J.I.* **182**, 7155–7162 (2009).
- 740 26. Valea, D. *et al.* CD4⁺ T cells spontaneously producing human immunodeficiency
741 virus type I in breast milk from women with or without antiretroviral drugs.
742 *Retrovirology* **8**, 34 (2011).
- 743 27. Wirt, D. P., Adkins, L. T., Palkowetz, K. H., Schmalstieg, F. C. & Goldman, A. S.
744 Activated and memory T lymphocytes in human milk. *Cytometry* **13**, 282–290
745 (1992).
- 746 28. Morzel, M. *et al.* Saliva electrophoretic protein profiles in infants: Changes with age
747 and impact of teeth eruption and diet transition. *Archives of Oral Biology* **56**, 634–
748 642 (2011).
- 749 29. Al-Shehri, S. S. *et al.* Breastmilk-Saliva Interactions Boost Innate Immunity by
750 Regulating the Oral Microbiome in Early Infancy. *PLoS ONE* **10**, e0135047 (2015).

- 751 30. Karhumaa, P. *et al.* The identification of secreted carbonic anhydrase VI as a
752 constitutive glycoprotein of human and rat milk. *Proc Natl Acad Sci USA* **98**, 11604–
753 11608 (2001).
- 754 31. Saleem, B. *et al.* Intestinal Barrier Maturation in Very Low Birthweight Infants:
755 Relationship to Feeding and Antibiotic Exposure. *The Journal of Pediatrics* **183**, 31–
756 36.e1 (2017).
- 757 32. Molès, J.-P. *et al.* Breastmilk cell trafficking induces microchimerism-mediated
758 immune system maturation in the infant. *Pediatr Allergy Immunol* **29**, 133–143
759 (2018).
- 760 33. Kinder, J. M. *et al.* Cross-Generational Reproductive Fitness Enforced by
761 Microchimeric Maternal Cells. *Cell* **162**, 505–515 (2015).
- 762 34. Stikvoort, A. *et al.* Long-Term Stable Mixed Chimerism after Hematopoietic Stem
763 Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?
764 *PLoS ONE* **11**, e0154737 (2016).
- 765 35. Kalimuddin, S. *et al.* Early T cell and binding antibody responses are associated
766 with Covid-19 RNA vaccine efficacy onset. *Med (N Y)* (2021).
767 doi:10.1016/j.medj.2021.04.003
- 768 36. Skelly, D. T. *et al.* Vaccine-induced immunity provides more robust heterotypic
769 immunity than natural infection to emerging SARS-CoV-2 variants of concern.
770 (2021). doi:10.21203/rs.3.rs-226857/v1
- 771 37. Tang, M. W., Garcia, S., Gerlag, D. M., Tak, P. P. & Reedquist, K. A. Insight into the
772 Endocrine System and the Immune System: A Review of the Inflammatory Role of
773 Prolactin in Rheumatoid Arthritis and Psoriatic Arthritis. *Front. Immunol.* **8**, 720
774 (2017).
- 775 38. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
776 *N Engl J Med* **383**, 2603–2615 (2020).
- 777 39. Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. & Leshem, E. Early rate reductions
778 of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *The*
779 *Lancet* **397**, 875–877 (2021).
- 780 40. Saito, S. *et al.* IgA tetramerization improves target breadth but not peak potency of
781 functionality of anti-influenza virus broadly neutralizing antibody. *PLoS Pathog* **15**,
782 e1007427 (2019).
- 783 41. la Flor St Remy, de, R. R., Sánchez, M. L. F., Sastre, J. B. L. & Sanz-Medel, A.
784 Multielemental distribution patterns in premature human milk whey and pre-term
785 formula milk whey by size exclusion chromatography coupled to inductively coupled
786 plasma mass spectrometry with octopole reaction cell. *J. Anal. At. Spectrom.* **19**,
787 1104–1110 (2004).
- 788 42. Goncalves, J. *et al.* Evaluating SARS-CoV-2 Seroconversion Following Relieve of
789 Confinement Measures. *Front. Med.* **7**, 603996 (2020).
- 790 43. Alenquer, M. *et al.* Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of
791 immune evasion affecting antibody but not ACE2 binding. *bioRxiv* 1–87 (2021).
792 doi:10.1101/2021.04.22.441007
- 793 44. Goel, R. R. *et al.* Distinct antibody and memory B cell responses in SARS-CoV-2
794 naïve and recovered individuals following mRNA vaccination. *Sci Immunol* **6**,
795 (2021).
- 796 45. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N*
797 *Engl J Med* **384**, 403–416 (2021).
- 798 46. Wilson, E. & Butcher, E. C. CCL28 controls immunoglobulin (Ig)A plasma cell
799 accumulation in the lactating mammary gland and IgA antibody transfer to the
800 neonate. *J Exp Med* **200**, 805–809 (2004).
- 801 47. Altmann, D. M. & Boyton, R. J. SARS-CoV-2 T cell immunity: Specificity, function,
802 durability, and role in protection. *Sci Immunol* **5**, (2020).
- 803 48. Sariol, A. & Perlman, S. Lessons for COVID-19 Immunity from Other Coronavirus
804 Infections. *Immunity* **53**, 248–263 (2020).

- 805 49.Ma, L. J., Walter, B., Deguzman, A., Muller, H. K. & Walker, A. M. Trans-epithelial
806 immune cell transfer during suckling modulates delayed-type hypersensitivity in
807 recipients as a function of gender. *PLoS ONE* **3**, e3562 (2008).
- 808 50.Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8
809 months after infection. *Science* eabf4063–23 (2021). doi:10.1126/science.abf4063
- 810 51.Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in
811 Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489–
812 1501.e15 (2020).
- 813 52.Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in
814 unexposed humans. *Science* eabd3871–11 (2020). doi:10.1126/science.abd3871
- 815 53.Liguoro, I. *et al.* SARS-COV-2 infection in children and newborns: a systematic
816 review. *Eur J Pediatr* **179**, 1029–1046 (2020).
- 817 54.Atyeo, C. & Alter, G. The multifaceted roles of breast milk antibodies. *Cell* **184**,
818 1486–1499 (2021).
- 819 55.Fox, A. *et al.* Robust and Specific Secretory IgA Against SARS- CoV-2 Detected in
820 Human Milk. *iScience* **23**, 101735 (2020).
- 821 56.Pace, R. M. *et al.* Characterization of SARS-CoV-2 RNA, Antibodies, and
822 Neutralizing Capacity in Milk Produced by Women with COVID-19. *mBio* **12**, 1757–
823 11 (2021).
- 824 57.Sterlin, D. *et al.* IgA dominates the early neutralizing antibody response to SARS-
825 CoV-2. *Sci Transl Med* **13**, (2021).
- 826 58.Wang, Z. *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl*
827 *Med* **13**, eabf1555 (2021).
- 828 59.Allman, D., Wilmore, J. R. & Gaudette, B. T. The continuing story of T-cell
829 independent antibodies. *Immunol. Rev.* **288**, 128–135 (2019).
- 830 60.Viana, J. F. *et al.* Population homogeneity for the antibody response to COVID-19
831 Comirnaty vaccine is only reached after the second dose. *medrxiv.org* (2021).
832 doi:10.1101/2021.03.19.21253680
- 833 61.Miller, R. A. Observations on the gastric acidity during the first month of life. *Arch*
834 *Dis Child* **16**, 22–30 (1941).
- 835 62.Wills, L. & Paterson, D. A Study of Gastric Acidity in Infants. *Arch Dis Child* **1**, 232–
836 244 (1926).
- 837 63.Moderbacher, C. R. *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2 in
838 Acute COVID-19 and Associations with Age and Disease Severity. *Cell* **183**, 996–
839 1012.e19 (2020).
- 840 64.Tan, A. T. *et al.* Early induction of functional SARS-CoV-2-specific T cells
841 associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell*
842 *Reports* **34**, 108728 (2021).
- 843 65.McMahan, K. *et al.* Correlates of protection against SARS-CoV-2 in rhesus
844 macaques. *Nature* **590**, 630–634 (2021).
- 845 66.Stadlbauer, D. *et al.* SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol
846 for a Serological Assay, Antigen Production, and Test Setup. *Current Protocols in*
847 *Microbiology* **57**, A.3A.1–15 (2020).
- 848 67.Stadlbauer, D. *et al.* Repeated cross-sectional sero-monitoring of SARS-CoV-2 in
849 New York City. *Nature* **590**, 146–150 (2021).
- 850
851
852
853
854
855
856
857
858
859

860
861
862
863
864
865
866
867

Table S1. Demographic data of nursing health care workers.

Nursing	Feeding duration (months)	Days post 1st dose	Days post 2nd dose	COVID-19 diagnostic
1	16	10	10	No
2	12	10	11	No
3	7	8	7	No
4	13	13	13	No
5	21	13	10	No
6	23	8	10	No
7	13	8	8	No
8	11	16	9	No
9	4	10	10	No
10	15	12	12	No
11	9	9	7	No
12	13	8	9	No
13	3	8	9	No
14	13	7	10	No

868
869

Table S2. Demographic data of controls health care workers.

Controls	Days post 2nd dose	COVID-19 diagnostic
1	10	No
2	16	No
3	10	No
4	10	No
5	10	No
6	10	No
7	10	No
8	11	No
9	11	No
10*	11	No

870 *Excluded from the study due to post-menopausal status.

Figure 1















Figure 2**A****B****C****D****E****F****G****H****I**

Figure 3


A




B




C



D



E



F




Figure 4






Figure S1**A****B**

Figure S1. Standardization of molecular weight range of the chromatographic separation. (A) Chromatogram of all standard proteins run in a Superdex 200 increase 10/300 GL. HWM Filtration Calibration Kit (Cytiva) were used with the following proteins: thyroglobulin (669 kDa); ferritin (450 kDa), aldolase (158 kDa), conalbumin (75 kDa) and ovalbumin (44 kDa). These standard proteins were dissolved in bi-distilled water and their chromatographic profiles were obtained using an UV detector. **(B)** Graphical representation of calibration curve of partition coefficient (K_{av}) of each protein versus their respective molecular weight in Daltons. The K_{av} was calculated through the following formula: $K_{av} = (V_e - V_0) / (V_c - V_0)$ where V_e is the elution volume of the protein, V_0 is the void volume and V_c is the column bed volume. A dispersion graph K_{av} vs $\log MW$ was constructed. The equation obtained for the calibration curve is: $K_{av} = -0.322 \log(MW) + 1.9436$, where K_{av} is the partition coefficient and MW is the protein molecular weight (Da).

Figure S2

A




Figure S2 - Size-exclusion chromatograms of breastmilk samples (Superdex 200 Increase 10/300 GL). (A) SEC- chromatograms of all breastmilk samples from first and second vaccine doses superposed.